Geistlich moves to deepen partnership with ReOss
Wolhusen/Schlieren/Filderstadt - Geistlich Pharma is expanding its partnership with the German company ReOss GmbH. In so doing, Geistlich has secured global marketing and distribution rights for Yxoss CBR, which is the main product of the dental medicine specialist.
Geistlich Pharma AG from Wolhusen in the canton of Lucerne, Switzerland, is making a strategic investment in its partner ReOss GmbH, as the company explains in a press release. Based in Filderstadt in the German federal state of Baden-Württemberg, ReOss is a developer of medical products for dentistry and oral, maxillofacial and facial surgery. ReOss offers patient-specific solutions that combine digital patient data with 3D printing technology, the press release states. With the expanded strategic alliance, Geistlich has secured the exclusive global marketing and distribution rights for the main product Yxoss CBR as well as for the pipeline technologies of ReOss.
With this investment, Geistlich is seeking to bolster its portfolio with the addition of the latest regenerative solutions, the company writes. «Geistlich is looking forward to continuing and enhancing the successful partnership with ReOss», comments Dr. Mark Spilker, CSO of Geistlich, adding that: «We are excited to further integrate regeneration into digital patient workflow through application of ReOss’s cutting-edge 3D patient-specific technologies». This will allow Geistlich’s dental customers «to tailor their treatments even more individually to each patient», Spilker concludes.
Geistlich describes ReOss in the press release as being renowned for leading-edge CAD/CAM technologies that leverage individual patient data to digitally create patient-specific solutions. The company’s 3D-printed products such as Yxoss CBR have already been commercialized across Europe and the USA, in addition to Australia and a range of other countries.
According to the information, the ReOss pipeline contains promising new digital-based technologies that will be made available to customers over the next few years. Geistlich Pharma is part of the Geistlich Group with its headquarters in Schlieren in the canton of Zurich.
